Trial Profile
Comparison of DPP4 inhibitors versus luseogliflozin, a SGLT2 inhibitor using cotinuous glucose monitoring (CGM)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Jun 2016
Price :
$35
*
At a glance
- Drugs Luseogliflozin (Primary) ; Dipeptidyl peptidase 4 inhibitors
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 21 Jun 2016 Status changed from recruiting to completed.
- 18 Jul 2014 New trial record